# Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/KPRX
## Company Profile
- Ticker: KPRX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Ophthalmology
## Stock Data
- Close: 2.54 USD
- Market cap: 12054876.8 USD
- Last updated: 2026-08-05
## Business Overview
### Retinal-Disease Pipeline
Kiora Pharmaceuticals develops small-molecule therapies for retinal diseases. Its programs are designed to improve vision or preserve retinal function through mechanisms distinct from conventional gene-specific approaches.
### KIO-301
KIO-301 is a light-sensitive small molecule intended to restore visual signaling in patients with inherited retinal degeneration by conferring light responsiveness on surviving retinal cells. It is being evaluated in the Phase 2 ABACUS-2 study.
### Additional Ophthalmic Program
Kiora's pipeline also includes a second clinical retinal program supported through collaboration funding, giving the company multiple opportunities to test its small-molecule approach in serious eye disease.
## Why The Stock Is Moving

The latest monitored company update is “Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- The main thing to watch at Kiora Pharmaceuticals is ABACUS-2, KIO-301, and the rest of its current pipeline. The update that sharpened the story was First Quarter 2026 and Recent Highlights Enrollment in the Phase 2 ABACUS-2 study of KIO-301 remains very active, with expansion of clinical trial sites to accommodate the strong.... That is the part of the story investors will probably keep circling back to.

## Drug Assets

- KIO-301

## Recent News
- 2026-08-07 11:00 EST — [Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-7b61887b) — Source: Kiora Pharmaceuticals
- 2026-07-02 11:00 EST — [Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium](https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-to-participate-in-piper-sandler-virtual-ophthalmology-symp-a9cd7ac0) — Source: Kiora Pharmaceuticals
- 2026-06-18 11:00 EST — [Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model](https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-reports-its-ion-channel-modulator-kio-300-suppressed-seizu-6aa93b6c) — Source: Kiora Pharmaceuticals
- 2026-05-08 11:00 EST — [Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Kiora Pharmaceuticals
- 2026-04-14 11:00 EST — [Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway](https://biopharmsignal.com/news/KPRX/kiora-s-phase-1-abacus-study-of-kio-301-in-retinitis-pigmentosa-published-in-nature-medicine-phase-2-trial-underway) — Source: Kiora Pharmaceuticals